US Patent Issued to UNIVERSITETET I OSLO on July 7 for "Engineered immunoglobulins with altered FcRn binding" (Norwegian Inventors)

ALEXANDRIA, Va., July 7 -- United States Patent no. 12,674,004, issued on July 7, was assigned to UNIVERSITETET I OSLO (Oslo, Norway).

"Engineered immunoglobulins with altered FcRn binding" was invented by Jan Terje Andersen (Oslo, Norway), Stian Foss (Oslo, Norway) and Inger Sandlie (Oslo, Norway).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life."

The patent was filed on April 12, 2022, under Application No. 17/719,227.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?...